Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Estrogen receptor β in Alzheimer's disease: From mechanisms to therapeutics.

Zhao L, Woody SK, Chhibber A.

Ageing Res Rev. 2015 Nov;24(Pt B):178-90. doi: 10.1016/j.arr.2015.08.001. Epub 2015 Aug 22. Review.

PMID:
26307455
2.

Blood pressure interacts with APOE ε4 to predict memory performance in a midlife sample.

Oberlin LE, Manuck SB, Gianaros PJ, Ferrell RE, Muldoon MF, Jennings JR, Flory JD, Erickson KI.

Neuropsychology. 2015 Sep;29(5):693-702. doi: 10.1037/neu0000177. Epub 2015 Mar 2.

PMID:
25730733
3.

Subjective cognitive concerns, episodic memory, and the APOE ε4 allele.

Samieri C, Proust-Lima C, M Glymour M, Okereke OI, Amariglio RE, Sperling RA, Rentz DM, Grodstein F.

Alzheimers Dement. 2014 Nov;10(6):752-759.e1. doi: 10.1016/j.jalz.2014.06.012. Epub 2014 Sep 23.

4.

Life extension factor klotho enhances cognition.

Dubal DB, Yokoyama JS, Zhu L, Broestl L, Worden K, Wang D, Sturm VE, Kim D, Klein E, Yu GQ, Ho K, Eilertson KE, Yu L, Kuro-o M, De Jager PL, Coppola G, Small GW, Bennett DA, Kramer JH, Abraham CR, Miller BL, Mucke L.

Cell Rep. 2014 May 22;7(4):1065-76. doi: 10.1016/j.celrep.2014.03.076. Epub 2014 May 10.

5.

CSF Apo-E levels associate with cognitive decline and MRI changes.

Toledo JB, Da X, Weiner MW, Wolk DA, Xie SX, Arnold SE, Davatzikos C, Shaw LM, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative.

Acta Neuropathol. 2014 May;127(5):621-32. doi: 10.1007/s00401-013-1236-0. Epub 2014 Jan 3.

6.

Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly.

Salmon DP, Ferris SH, Thomas RG, Sano M, Cummings JL, Sperling RA, Petersen RC, Aisen PS.

Neuropsychology. 2013 Jul;27(4):391-401. doi: 10.1037/a0032707.

7.

Characterization of vascular disease risk in postmenopausal women and its association with cognitive performance.

Dowling NM, Gleason CE, Manson JE, Hodis HN, Miller VM, Brinton EA, Neal-Perry G, Santoro MN, Cedars M, Lobo R, Merriam GR, Wharton W, Naftolin F, Taylor H, Harman SM, Asthana S.

PLoS One. 2013 Jul 17;8(7):e68741. doi: 10.1371/journal.pone.0068741. Print 2013.

8.

APOE ε4, Alzheimer's disease pathology, cerebrovascular disease, and cognitive change over the years prior to death.

Yu L, Boyle P, Schneider JA, Segawa E, Wilson RS, Leurgans S, Bennett DA.

Psychol Aging. 2013 Dec;28(4):1015-23. doi: 10.1037/a0031642. Epub 2013 May 6.

9.

Alternative Approaches in Gene Discovery and Characterization in Alzheimer's Disease.

Ertekin-Taner N, De Jager PL, Yu L, Bennett DA.

Curr Genet Med Rep. 2013 Mar;1(1):39-51. Epub 2013 Jan 22.

10.

Accelerated cell aging in female APOE-ε4 carriers: implications for hormone therapy use.

Jacobs EG, Kroenke C, Lin J, Epel ES, Kenna HA, Blackburn EH, Rasgon NL.

PLoS One. 2013;8(2):e54713. doi: 10.1371/journal.pone.0054713. Epub 2013 Feb 13.

11.

ApoE and quality of life in nonagenarians.

Parsaik AK, Lapid MI, Rummans TA, Cha RH, Boeve BF, Pankratz VS, Tangalos EG, Petersen RC.

J Am Med Dir Assoc. 2012 Oct;13(8):704-7. doi: 10.1016/j.jamda.2012.06.012. Epub 2012 Aug 3.

12.

Mild cognitive impairment, dementia, and their subtypes in oldest old women.

Yaffe K, Middleton LE, Lui LY, Spira AP, Stone K, Racine C, Ensrud KE, Kramer JH.

Arch Neurol. 2011 May;68(5):631-6. doi: 10.1001/archneurol.2011.82.

13.

Do aromatase inhibitors have adverse effects on cognitive function?

Phillips KA, Ribi K, Fisher R.

Breast Cancer Res. 2011 Feb 23;13(1):203. doi: 10.1186/bcr2806. Review.

14.

An Update on Postoperative Cognitive Dysfunction.

Tsai TL, Sands LP, Leung JM.

Adv Anesth. 2010;28(1):269-284. No abstract available.

15.

Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects.

Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Jack CR Jr, Aisen PS, Petersen RC, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2010 Nov 30;75(22):1976-81. doi: 10.1212/WNL.0b013e3181ffe4d1. Epub 2010 Oct 27.

16.

Sex differences in the association of the apolipoprotein E epsilon 4 allele with incidence of dementia, cognitive impairment, and decline.

Beydoun MA, Boueiz A, Abougergi MS, Kitner-Triolo MH, Beydoun HA, Resnick SM, O'Brien R, Zonderman AB.

Neurobiol Aging. 2012 Apr;33(4):720-731.e4. doi: 10.1016/j.neurobiolaging.2010.05.017. Epub 2010 Jul 8.

17.

Physical activity over the life course and its association with cognitive performance and impairment in old age.

Middleton LE, Barnes DE, Lui LY, Yaffe K.

J Am Geriatr Soc. 2010 Jul;58(7):1322-6. doi: 10.1111/j.1532-5415.2010.02903.x. Epub 2010 Jun 30.

18.

APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.

Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA.

Ann Neurol. 2010 Jan;67(1):122-31. doi: 10.1002/ana.21843.

19.

Effects of family history and apolipoprotein E epsilon4 status on cognitive decline in the absence of Alzheimer dementia: the Cache County Study.

Hayden KM, Zandi PP, West NA, Tschanz JT, Norton MC, Corcoran C, Breitner JC, Welsh-Bohmer KA; Cache County Study Group.

Arch Neurol. 2009 Nov;66(11):1378-83. doi: 10.1001/archneurol.2009.237.

20.

Olfaction in aging and Alzheimer's disease: event-related potentials to a cross-modal odor-recognition memory task discriminate ApoE epsilon4+ and ApoE epsilon 4- individuals.

Murphy C, Solomon ES, Haase L, Wang M, Morgan CD.

Ann N Y Acad Sci. 2009 Jul;1170:647-57. doi: 10.1111/j.1749-6632.2009.04486.x.

Items per page

Supplemental Content

Write to the Help Desk